Read it.
You don't have to agree with everything she says. But whether you agree or not, remember that Science Always Wins.
Viva Garagista!
Rob Carlson (Home)
Book :: www.biologyistechnology.com
Biodesic :: www.biodesic.com
Twitter :: @rob_carlson
The cost burden of the disease on individual families is highly regressive. The average cost per household for treating malaria may be in the range of only 3-7 percent of income, but total and indirect costs to poor households can amount to one-third of annual income. The disease also disproportionately affects the young. Approximately 90percent of those who are killed by the parasite are African children under the age of five; according to the World Health Organization (WHO), a child dies from malaria roughly every thirty seconds.So, Mr. Thomas, what about all the people who will benefit from inexpensive malaria drugs? It is, frankly, unconscionable and indefensible for you to continue beating this drum as you do. The human cost of not producing inexpensive artemisinin in vats is astronomical. If reducing the burden of malaria around the world on almost 2 billion people might harm "a few thousand" farmers, then we should make sure those farmers can make a living growing some other crop. We can solve both problems. Your ideological opposition to synthetic biology is is blinding you to the opportunities, and your version of reality would ignore the health and welfare of children around the world.
In addition to staggering personal costs, the disease harms whole societies by severely inhibiting economic development. In affected countries, malaria reduces GDP growth by about 1.3 percent per year. These countries, moreover, contain about 40percent of the world's population. Over the past forty years, the growth penalty has created a difference in GDP that substantially exceeds the billions in annual foreign aid they receive. In 2000 the World Health Organization estimated that eliminating this growth penalty in 1965 would have resulted in "up to $100 billion added to sub-Saharan Africa's [2000] GDP of $300 billion. This extra $100 billion would be, by comparison, nearly five times greater than all development aid provided to Africa [in 1999]."
Because there was no technical means to eliminate the parasite in the middle of the twentieth century, this is clearly a number calculated to impress or shock, but the point is that the growth penalty continues to balloon. As of 2008, the GDPs of countries in sub-Saharan Africa would be approximately 35 percent higher than they are today had malaria been eliminated in 1965. The World Health Organization reckons that malaria-free countries have a per capita GDP on average three times larger than malarious countries. The productivity of farmers in malarious countries is cut by as much as 50 percent because of workdays lost to the disease. The impact of producing an effective and inexpensive antimalarial drug would therefore be profound.
Improving access to other technologies, such as bed nets treated with insecticides, would also be of substantial aid in reducing the rate of infection. Yet infected victims will still need access to cures. Prevention might be found in a vaccine, which the Gates Foundation also funds. However, even the most promising malaria vaccine candidates are only partially effective and cost even more than artemisinin. Microbial production of artemisinin would completely change the impact of malaria on billions of people worldwide. Artemisinin is presently derived from the wormwood tree and has been used as an herbal remedy for at least two thousand years. Its antimalarial activity was first described by Chinese scientists in 1971. The existence of the drug and its physiochemical properties were announced to the world in 1979, although its precise molecular mechanism of action is still not understood. A method for chemical synthesis was published in 1983, but it remains "long, arduous, and economically nonviable."
Because natural artemisinin is an agricultural product, it competes for arable land with food crops, is subject to seasonal variations in supply, and its production costs are in part determined by the costs of fertilizer and fuel. As a result of the work of Keasling and his collaborators, it appears that, within just a few years, biological technology may provide a more-flexible and less-expensive supply of drugs than now exists. Commercial production of artemisinin should commence in 2010, with a continuous annual production sufficient to treat the 500million malaria cases per year.
|
Indus |
151% |
|
Brahmaputra |
27% |
|
Ganges |
10% |
|
Yangtze |
8% |
|
Yellow |
8% |
We conclude that Asia's water towers are threatened by climate change, but that the effects of climate change on water availability and food security in Asia differ substantially among basins and cannot be generalized. The effects in the Indus and Brahmaputra basins are likely to be severe owing to the large population and the high dependence on irrigated agriculture and meltwater. In the Yellow River, climate change may even yield a positive effect as the dependence on meltwater is low and a projected increased upstream precipitation, when retained in reservoirs, would enhance water availability for irrigated agriculture and food security.I am perplexed by the take on these results over at Nature News by Richard Lovett. His piece carries the title, "Global warming's impact on Asia's rivers overblown". I'll give Lovett the out that he may not have written the actual headline (Editors!), but nonetheless he sets up the Immerzeel paper as a big blow to some unnamed group of doomsayers. Perhaps he imagines that Immerzeel completely undermines the IPCC report? This is hardly the case. As I wrote last January, sorting out the mistake over Himalayan melting rates is an example of science working through a blunder. Instead overturning some sort of vague conspiracy, as best I can tell Immerzeel is simply the first real effort to make quantitative assessments of something to which much more attention should have been paid, much earlier than it was.
The findings are important for policy-makers, says Jeffrey Kargel, a glaciologist at the University of Arizona in Tucson. "This paper adds to mounting evidence that the Indus Basin [between India and Pakistan] is particularly vulnerable to climate change," says Kargel. "This is a matter that obviously concerns India and Pakistan very much."Indeed. As they should concern us all.